LRMR 4.01 (+0.75%)
US5171251003BiotechnologyBiotechnology

Larimar Therapeutics (LRMR) Financial Metrics

This table shows a selected set of financial data points of Larimar Therapeutics (LRMR). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -0.84 0 -5.41 199.75M -0.33 0 -33.62M -41.45M -36.95M 26.75M
2022 -1.37 0 -3.01 106.39M -0.34 0 -27.67M -36.21M -35.36M 26.83M
2021 -2.95 0 -3.66 185.2M -0.55 0 -42.44M -50.14M -50.64M 70.1M
2020 -3.58 0 -5.99 254.42M -0.77 0 -42.26M -42.65M -42.48M 68.15M
2019 -2.51 0 -0.44 10.23M -0.36 0 -22.78M -23.14M -23.13M 1.01M
2018 -22.85 0 -0.22 13.29M -0.54 0 -51.6M -61.35M -61.37M 49.33M
2017 -22.76 0 -0.2 10.56M -0.44 0 -43.84M -50.87M -52.03M 40.78M
2016 -25.44 0 -0.13 7.23M -0.36 0 -52.64M -57.32M -57.88M 32.35M
2015 -33.32 0 -0.19 14.02M 0 0 -60.15M -74.69M -74.29M 35.6M
2014 0 0 0 30.84M 0 0 0 0 0 0

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.